ID   SCLC-86M1
AC   CVCL_8263
SY   MAR-86MI; MAR 86MI; MAR86M1; MAR86MI; MAR 86 MI; 86MI; 86M1
DR   Cosmic; 2648019
DR   Wikidata; Q54952447
RX   PubMed=1845952;
RX   PubMed=2438285;
RX   PubMed=2473086;
RX   PubMed=2574988;
RX   PubMed=3029138;
RX   PubMed=9744504;
RX   PubMed=12712436;
CC   Characteristics: Established from a first passage xenograft maintained in nude mice.
CC   Doubling time: 70 hours (PubMed=2438285).
CC   Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
DI   NCIt; C4917; Lung small cell carcinoma
DI   ORDO; Orphanet_70573; Small cell lung cancer
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_X024 ! SCLC-86M2
SX   Female
AG   74Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 29-06-23; Version: 14
//
RX   PubMed=1845952; DOI=10.1002/1097-0142(19910201)67:3<619::AID-CNCR2820670317>3.0.CO;2-Y;
RA   Broers J.L.V., Mijnheere E.P., Rot M.K., Schaart G., Sijlmans A.,
RA   Boerman O.C., Ramaekers F.C.S.;
RT   "Novel antigens characteristic of neuroendocrine malignancies.";
RL   Cancer 67:619-633(1991).
//
RX   PubMed=2438285; DOI=10.1007/BF00396382;
RA   Bepler G., Jaques G., Koehler A., Gropp C., Havemann K.;
RT   "Markers and characteristics of human SCLC cell lines. Neuroendocrine
RT   markers, classical tumor markers, and chromosomal characteristics of
RT   permanent human small cell lung cancer cell lines.";
RL   J. Cancer Res. Clin. Oncol. 113:253-259(1987).
//
RX   PubMed=2473086; DOI=10.1242/jcs.91.1.91;
RA   Broers J.L.V., Rot M.K., Oostendorp T., Bepler G., de Leij L.F.M.H.,
RA   Carney D.N., Vooijs G.P., Ramaekers F.C.S.;
RT   "Spontaneous changes in intermediate filament protein expression
RT   patterns in lung cancer cell lines.";
RL   J. Cell Sci. 91:91-108(1988).
//
RX   PubMed=2574988; DOI=10.1038/bjc.1989.376; PMCID=PMC2247271;
RA   Jensen P.B., Vindelov L.L., Roed H., Demant E.J.F., Sehested M.,
RA   Skovsgaard T., Hansen H.H.;
RT   "In vitro evaluation of the potential of aclarubicin in the treatment
RT   of small cell carcinoma of the lung (SCCL).";
RL   Br. J. Cancer 60:838-844(1989).
//
RX   PubMed=3029138; DOI=10.1007/BF00389964;
RA   Bepler G., Jaques G., Neumann K., Aumuller G., Gropp C., Havemann K.;
RT   "Establishment, growth properties, and morphological characteristics
RT   of permanent human small cell lung cancer cell lines.";
RL   J. Cancer Res. Clin. Oncol. 113:31-40(1987).
//
RX   PubMed=9744504; DOI=10.1038/bjc.1998.553; PMCID=PMC2063065;
RA   Damstrup L., Voldborg B.G.R., Spang-Thomsen M., Brunner N.,
RA   Poulsen H.S.;
RT   "In vitro invasion of small-cell lung cancer cell lines correlates
RT   with expression of epidermal growth factor receptor.";
RL   Br. J. Cancer 78:631-640(1998).
//
RX   PubMed=12712436; DOI=10.1002/ijc.11106;
RA   Hansen L.T., Lundin C., Spang-Thomsen M., Petersen L.N., Helleday T.;
RT   "The role of RAD51 in etoposide (VP16) resistance in small cell lung
RT   cancer.";
RL   Int. J. Cancer 105:472-479(2003).
//